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BACKGROUND: C-arm cone-beam computed tomography (CBCT) is a comparatively novel modality for guiding
percutaneous transthoracic lung biopsies (PTLBs), and despite its potential advantages over conventional
computed tomography (CCT), a head-to-head comparison of the two techniques has yet to be reported in the
literature. This study aims to evaluate the diagnostic value and safety of CBCT-guided PTLB compared to CCT-
guided biopsy, with cases performed in a single hospital. METHODS: A total of 104 PTLB patients were
retrospectively analyzed in this study. 35 PTLBs were performed under CBCT guidance, and 69 PTLBs were
performed under CCT guidance. Diagnostic accuracy, sensitivity, and specificity for malignancy as well as
procedure time, radiation dose of patients, and complication rate in the two groups were compared. RESULTS:
Total procedure timewas significantly lower in theCBCTgroup (32±11minutes) compared to theCCTgroup (38±9.7
minutes; P= .009), especially among patients≥70 years of age (CBCT: 33± 12minutes, CCT: 42± 13, P= .022). For
lesions in the lower lobes, the CBCT-guided group received significantly reduced effective radiation dose (2.9 ± 1.6
mSv) than CCT-guided patients (3.7 ± 0.80; P= .042). Diagnostic accuracy, sensitivity, and specificity for malignancy
were comparable between the two groups, as were post-biopsy complication rates. CONCLUSION: CBCT guidance
significantly reduces the procedure time and radiation exposure for PTLBs compared with CCT, and should be
considered in clinical settings that may be difficult or time-consuming to perform under CCT.
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Upon the detection of a suspicious pulmonary mass by any imaging
modality, tissue samples are usually sought as part of the clinical
assessment. Bronchoscopy is often the first step, as it allows both
direct observation of the lung mass to evaluate its characteristics and
extent and also to conduct tissue sampling. Although diagnostic rates
of up to 80% have been reported depending on the method used to
acquire tissues, bronchoscopic biopsy is limited to centrally located
tumors that are visible from within the airways [1].
For lesions that cannot be approached through bronchoscopy, a
percutaneous lung biopsy is usually performed under image guidance.
Ultrasound and computed tomography (CT) are the two most
commonly used guidance techniques, each with its own advantages
and disadvantages. While ultrasound provides real-time feedback for
relatively quick and inexpensive biopsy, its utility is limited to either
pleural-based masses or lesions located within a short distance of thepleura [2]. CT-guided procedures are the current standard for
transthoracic needle biopsy of pulmonary masses and enjoy high
diagnostic accuracy and widespread availability [3,5]. Spatial
resolution is high and serious complications are rare in the hands of
experienced practitioners [4]. Its primary drawback lies in the absence
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available in conventional fluoroscopy guidance systems. For deep
pulmonary masses requiring oblique needle angles (for example, to
avoid major vessels, ribs, or airways) and in older patients who have
difficulty holding their breath, the procedure time and subsequent
radiation doses are often increased [4]. Additionally, owing to the
ever-expanding role of CT in both diagnosis and screening [5], sharing
valuable scanning time with potentially time-consuming biopsy
procedures creates both an administrative burden in terms of patient
scheduling and a financial burden in terms of reduced CT scans.
Initially used for neurovascular imaging, flat panel cone-beam CT
systems have in recent years been applied in image-guided
percutaneous procedures [6]. By combining a C-arm gantry with
cone-beam X-ray tube and flat panel detectors, C-arm cone-beam CT
(CBCT) incorporates the imaging resolution of conventional CT
(CCT) with the real-time needle guiding capability of fluoroscopic
systems. [7] With the aid of path-planning software and the rotational
capability of a C-arm, CBCT allows an operator to approach lesions
that are difficult to reach under CCT with greater confidence. Recent
studies have given promising initial descriptions on the accuracy and
safety of CBCT-guided biopsies performed on pulmonary masses,
which are comparable to previously reported results for CCT
[7,8,11].
Despite its potential for reducing procedure times and radiation
doses in the biopsy of pulmonary masses [8,11,14], CBCT-guided
biopsy has yet to be directly compared to CCT. In this study, we
retrospectively compare the diagnostic success, procedure time,
radiation exposure, and safety of lung mass biopsies performed
within a single hospital, under either cone-beam or CCT guidance.
Materials and Methods
Study Population and Patient Selection
From March to December of 2013, 104 consecutive patients who
received percutaneous transthoracic lung biopsies (PTLBs) were
retrospectively included in this study. PTLBs were scheduled under
CBCT or CCT imaging guidance according to operating room
availability. 35 PTLBs were performed under CBCT guidance (20
males and 15 females; mean age, 69 ± 12 years; age range, 42-89
years; group A) by one experienced thoracic radiologist (S.-H.T.), and
69 PTLBs were performed under CCT guidance (35 males and 34
females; mean age, 62 ± 13 years; age range, 31-89 years; group B) by
two experienced thoracic radiologists (S.-H.T. with 4 years of
experience and Y.-C.C. with 5 years of experience).
Hemograms and coagulation profiles were assessed for all patients
before biopsy, and only patients with a platelet count of 10,000/ml or
higher and international normalized ratio of 1.4 or less went on to
receive percutaneous biopsies. Any anticoagulants or platelet
inhibitors regularly taken by patients were withheld for at least 3
days before PTLB. After the procedure, all patients were kept under
observation at our hospital, and an erect chest radiograph was
arranged 4 hours later to detect potential late complications. In cases
of marked changes in vital signs or clinical status, repeat pulmonary
radiographs were taken.
Overview of Biopsy Procedure
All PTLBs were performed under local anesthesia, using either a
64-detector CT scanner (Brilliance 64; Philips Healthcare, Best, The
Netherlands) or a CBCT virtual navigation guidance system (XperCTand XperGuide software, AlluraXperFD20; Philips Healthcare). A
coaxial cutting needle technique was employed, using an 18-gauge
cutting needle and a 17-gauge coaxial introducer needle (Temno
Biopsy Device). Patients were placed in either supine or prone
positions depending on their lesion location and the presence of
overlying ribs or large blood vessels. Before each biopsy, we performed
a pre-procedural CT or CBCT scan of the entire lung to identify the
safest and most accessible route to reach the target nodule(s), while
avoiding obstacles and minimizing pleural contact and the distance
traveled by the needle through lung parenchyma. For CBCT
procedures, angulation of the biopsy needle was kept to the vertical
plane of rotation as much as possible so as to reduce complexity of
needle course planning and increase accuracy. Each CT or CBCT
scan was performed during a single breath-hold in either inspiration
or expiration, as best tolerated by each patient. Post-procedural CT or
CBCT images were acquired after biopsy completion to identify
procedure-related complications.
Protocol for CCT Guidance
For each patient before PTLB, we obtained low-dose axial CT scan
on a 64-detector scanner (Brilliance 64; Philips Healthcare) under the
following imaging parameters: 120 kVp, 30 mA per slice,
0.75-second rotation time, and collimation of 8 × 5 mm. The
window center and width were 0 and 2800 HU, respectively, which
allowed simultaneous visualization of vessels, tumor, pneumothorax,
bone, muscle, and fat. Once a skin entry site had been determined
and the coaxial introducer needle inserted into the subcutaneous
tissue, additional CT scans were performed before each needle course
correction so as to precisely position the needle tip within the target
lesion. Each procedure was performed with a “move off and scan”
approach to minimize radiation exposure to the operator [9].
Protocol for CBCT Guidance
CBCT was performed with the C-arm rotating 240° in 4 seconds,
generating 242 images in a 512 × 512 matrix. The acquired CBCT
images were transferred to commercially available dedicated medical
imaging workstations, where the safest and most effective skin entry
site and needle pathway to reach target lesion were determined
(Figure 1A). Distances from needle skin entry site to lesion and skin
to pleura were also measured and recorded. Virtual guidance
(XperGuide; Philips Healthcare) with automatic angle alignment
from the skin entry site to the target lesion (bull’s-eye view) was then
used along with virtual color overlay on the fluoroscopic image
(Figure 1B) to guide insertion of a 17-gauge coaxial introducer needle
into the target nodule. At this point, a procedural cone-beam CT scan
was performed to check the exact needle tip location (Figure 1, C
and D). If the introducer needle was correctly situated with tip
adjacent to the target lesion, an 18-gauge semi-automated cutting
needle was inserted into the target lesion through the introducer and a
tissue sample was obtained. After sufficient samples were obtained,
the coaxial introducer was removed.
Data Collection and Interpretation
For each patient enrolled in this study, all relevant medical history,
radiology reports, and histopathology data from biopsy and
subsequent surgery (if any) were retrospectively collected, followed
by immediate de-identification of all patient information. Final
diagnosis of target lung lesions was confirmed in the following ways.
Pathologic report of malignancy from a PTLB sample was accepted as
AC
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Figure 1. Cone-beam CT-guided transthoracic lung biopsy of a 1.5-cm left lower lobe nodule in an 80-year-old man. (A) Selection of skin
entry site after initial planning CBCT scan, with placement of needle along an inclined axis as aided by the path-guiding software. The
skin-to-pleura and skin-to-lesion distances were recorded during planning. (B) Bull’s-eye view of a pulmonary nodule, with red and green
circles to help align the biopsy needle with the target lesion. Real-time graphics overlay (in blue) displays the original position of a patient’s
target lesion during planning relative to its current position as it changes owing to patient motion. (C and D) Axial and sagittal views as
shown during CBCT-guided needle insertion, allowing vertical angle adjustments that facilitate avoidance of intervening obstacles such
as ribs and vascular structures.
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examination of subsequent surgically resected specimen, in which case
it was counted as false-positive. A benign PTLB result was considered
true-negative if the target lesion remained stable in size or regressed
20% or more during follow-up CT examination (6 months) in the
absence of medical treatment [17], or if surgical resection revealed a
specific benign pathology such as tuberculosis or hamartoma.
Conversely, if the presence of malignant pathology was confirmed
in a surgical specimen following PTLB result of benign lesion, the
case was considered false-negative. Using these criteria, the sensitivity,
specificity, and diagnostic accuracy of CBCT- and CCT-guided
biopsy procedures were calculated.
Sizes and depths of target lesions were evaluated during pre-biopsy
CBCT or CCT scan for each patient. Nodule size was defined as the
longest diameter of the lesion on lung-window CT images, while
lesion depth was calculated by subtracting skin-to-pleura distance
from skin-to-lesion distance on CT or CBCT planning view. The
distance from pleura to lung nodule was selected over skin-to-lesion
distance for two reasons: first, because the depth of needle passage
into lung parenchyma is more likely to influence the incidence of
pneumothorax and hemoptysis [21] and, second, to reduce the
confounding factor of patient’s physical build that affects skin-to-
pleura distance. We also recorded the following factors for each
PTLB: the number of biopsies performed, the patient’s relativeposition during biopsy, the number of CCT or CBCT scans, total
procedure time, and whether any complications developed. Total
procedure time was defined as the time interval from start of first
pre-biopsy CT scan to the last post-procedure scan, and complica-
tions were defined according to the guidelines described by Manhire
et al. [26] The number of CT scans performed for needle adjustment
in each patient was also calculated on the basis of the total number of
CT scans subtracted by the number of pre-procedural and
post-procedural scans. Procedures with complications that did not
require invasive interventions were defined as minor complications,
including hemoptysis and pneumothorax that resolved without
pig-tail or chest tube drainage. A complication was considered major
if additional treatment was needed (e.g., tube placement for a large
pneumothorax and intubation for post-procedure respiratory distress).
A pneumothorax detected on post-biopsy chest plain film was graded as
small if no chest tube placement was necessary, and large if tube
placement was performed.
Patient radiation exposure data during each PTLB procedure was
also collected for both CBCT and CCT cases. Absorbed radiation
doses for CBCT-guided biopsies were measured in terms of dose area
product (DAP, mGy cm2), while the dose length product (mGy cm)
was documented for procedures done under CCT guidance. DAP,
defined as the sum of absorbed radiation by fluoroscopy and CBCT
acquisition during the entire procedure, was converted into effective
Table 2. Location of Pulmonary Lesions and Patient Orientation during Procedure
CBCT (n = 35) CT (n = 69) P Value
Lesion location .3 *
RUL 15 (43) 21 (30)
RML 3 (9) 2 (3)
RLL 8 (23) 16 (23)
LUL 5 (14) 18 (26)
LLL 4 (11) 12 (17)
Patient position .7 *
Supine 16 (46) 27 (39)
Prone 18 (51) 41 (59)
Oblique 1 (3) 1 (2)
Numbers in parentheses indicate percentage within each group.
RUL, right upper lobe; RML, rightmiddle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe.
* χ2 test.
Table 3. Procedure Times, Radiation Exposure, and Safety of Lung Biopsy Guided by CBCT
Compared to CCT
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determined by Braak et al. under the same CBCT system used in this
study [8]. Dose length product was likewise converted into effective
dose using a factor of 0.02 mSv/mGy cm [25].
Statistical Analysis
Owing to the nonparametric distribution of data collected in this
study, comparisons between CBCT and CCT groups were performed
with Chi-squared test for qualitative variables and with Wilcoxon
rank-sum test for quantitative variables. For all analyses, a two-sided
P value smaller than .05 was considered statistically significant.
Statistical analysis was performed with SPSS software (version 22.0;
SPSS, Chicago, IL).
Results
Demographic and Lesion Characteristics of the Study Groups
Selected baseline characteristics for the CBCT and CCT groups are
shown in Table 1. Mean age for the 35 patients who underwent
CBCT-guided biopsy was higher than in the CCT biopsy group
(CBCT = 69 years, CCT = 63 years, P b .01), while gender distribution
was relatively even (F:M = 15:20 for CBCT, F:M = 35:34 for CCT).
Mean body weight of the patients across the two groups were likewise
similar (CBCT = 63 kg, CCT = 64 kg).
Themean pleura-to-lesion distance in theCBCTgroup (43± 17mm)
was similar to that for patients in the CCTgroup (37 ± 13mm), with the
size of each lesion biopsied being displayed in Table 1. Approximately
50% of lesions were in the size range of 20 to 39 mm in both groups.
There was also no significant difference in the distribution of lesion
locations between the two groups, as listed in Table 2.
Procedure Duration and Radiation Dose
Total procedure time was significantly shorter for CBCT group
patients (32 ± 11 minutes; range 20-70 minutes; Table 1) than for the
CCT group (38 ± 9.7 minutes; range 24-80 minutes; P b .01).
Further subgroup analysis revealed that procedure time difference
between the two guidance methods was greater in patients 70 years or
older (33 ± 12 minutes for CBCT, 42 ± 13 minutes for CCT, P =
.022). The mean number of CT scans performed for needle
adjustment during CBCT biopsy was also much lower than in the
CCT group (1.8 ± 1.0 times for CBCT, 10 ± 3.8 for CCT, P b .001),Table 1. Characteristics of the Patients and Pulmonary Lesions in Cone-Beam and CCT Groups
CBCT (n = 35) CT (n = 69) P Value
Mean age ± SD (years) 69 ± 2 * 62 ± 1.5 .009 †
b70 58 ± 6.2 55 ± 7.4 .21 †
≥70 79 ± 4.8 77 ± 5.4 .52 †
Mean body weight ± SD (kg) 63 ± 12 64 ± 12 .68 †
Gender
Female 15 (43) 35 (51) .54 ‡
Male 20 (57) 34 (49)
Lesion size (mm)
b10 1 (3) 4 (6)
10-19 5 (14) 8 (11)
20-29 16 (46) 20 (29)
30-39 4 (11) 14 (20)
40-49 5 (14) 10 (14)
≥50 4 (11) 13 (19)
Mean size ± SD 30 ± 14 35 ± 19 .16 †
Mean pleura-to-lesion depth ± SD (mm) 43 ± 17 37 ± 13 .08 †
* P b .05.
† Wilcoxon signed-rank test.
‡ χ2 test.although the total scan time was comparable (CBCT = 7.1 ± 3.7
seconds, CCT = 7.6 ± 2.8 seconds, P = .42) because of rotational
speed limitations of the C-arm in cone-beam systems.
Mean effective dose was lower in the CBCT group (3.4 ± 2.1 mSv)
compared to the CCT group (3.9 ± 0.79 mSv), and although there
was no statistical significance (P = .07) for the overall study groups,
dose was significantly lower for lesions in the lower lobes (2.9 ±
1.6 mSv for CBCT, 3.7 ± 0.80 mSv for CCT, P = .042). Despite
shorter total procedure times and reduced patient dose, the mean
number of cutting needle passes performed during each biopsy was
still significantly higher in CBCT patients than for CCT patients
(CBCT = 4.3 ± 0.9, CCT = 3.7 ± 1.2, P = .009), which was valuable
for acquiring adequate tissues for pathologic analysis.
Safety and Accuracy of Procedure
There was no statistically appreciable difference in post-biopsy
complication rates between the two different guidance methods,
although the cone-beam guidance method had proportionally less
complications overall (Table 3). Minor complications arose in 10 of
35 patients (29%) in the CBCT group and 16 of 69 patients (23%) in
the CCT group, with a significance level of P = .72. Major
complications involve post-procedure pneumothorax patients for
whom chest tube had to be placed, with only one patient from eachCBCT CT P Value
Mean total procedure time ± SD (minutes) 32 ± 11 * 38 ± 9.7 .009 †
b70 years 31 ± 13 37 ± 13 .075 †
≥70 years 33 ± 12 * 42 ± 13 .022 †
Mean effective dose ± SD (mSv) 3.4 ± 2.1 3.9 ± 0.79 .074 †
Lower lobes 2.9 ± 1.6 * 3.7 ± 0.80 .042 †
Upper/middle lobe 3.6 ± 2.3 4.0 ± 0.79 .44
Mean number of CT scans per biopsy # 1.8 ± 1.0 10 ± 3.8 b .001
Mean needle passes per biopsy 4.3 ± 0.9 * 3.7 ± 1.2 .011 †
Post-biopsy complications
Minor § 10 (28) 16 (23) .72 ‡
Major § 1 (3) 1 (1)
Hemoptysis 4 (11) 5 (7) .47 ‡
Pneumothorax 7 (20) 14 (20) .23 ‡
Mean hospitalization time (days) ¶ 3.3 ± 2.6 3.2 ± 2.0 .99 †
Numbers in parentheses indicate percentage within each group.
* P b .05.
† Wilcoxon signed-rank test.
‡ χ2 test.
§ Minor, post-biopsy hemoptysis or pneumothorax that was spontaneously resolved. Major, post-biopsy
pneumothorax requiring additional treatment, including chest tube and intubation.
¶ Days in hospital because of post-biopsy pneumothorax.
# Excluding routine pre-procedural and post-procedural CT scans.
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was a 65-year-old woman with a medical history of chronic
obstructive pulmonary disease, who underwent biopsy for a 3.4-cm
right middle lobe nodule. She suffered from hemoptysis and
parenchymal hemorrhage with progressive dyspnea soon after biopsy,
and eventually required endotracheal intubation with assisted
ventilation. She was safely discharged after 2 weeks of additional
treatment at our hospital. Her counterpart in the CCT group was a
75-year-old woman who had to receive chest tube drainage for 2 days
after biopsy, also because of progressive dyspnea. Further analysis of
the time spent in hospital as a result of post-biopsy pneumothorax
revealedminimal difference betweenCBCT (11 patients; 3.3 ± 2.6 days)
and CCT (17 patients; 3.2 ± 2.0 days) groups.
Sensitivity and specificity of biopsy results for the CBCT and CCT
groups compared to their final diagnosis are listed as follows. There
were 33 malignant and 2 benign cases in the CBCT group, with
biopsy demonstrating only chronic inflammation in 1 of the cases
that turned out to be invasive adenocarcinoma. The sensitivity and
specificity for malignant lesions in this group were 97% and 100%,
respectively, with an accuracy of 97%. For the CCT group, there were
54 malignant and 15 benign cases, with biopsy sensitivity, specificity,
and accuracy of 100%.
Discussion
Flat-panel CBCT systems designed specifically for guiding percuta-
neous needle procedures have only recently become commercially
available, after initial use in the field of interventional angiography
[10]. Its primary advantage over existing CT-guided techniques is the
addition of real-time imaging during needle insertion, which
simplifies needle path planning and increases the chance of reaching
target lesions. Additionally, there is potential for reducing procedure
times and thus radiation doses for patients [11,12]. A recent study has
shown favorable results in using CBCT to direct percutaneous bone
biopsies [13], with reduced radiation doses to the patient and
operator. Although previous authors have established that CBCT is a
valuable technique in image-guided biopsies, a direct comparison of
its accuracy, safety, and radiation exposure to the current standard of
CT guidance has yet to be performed for pulmonary lesions, which
almost always requires a biopsy before further surgical or medical
management. This study provides a head-to-head assessment of
CBCT- and CCT-guided lung biopsies in terms of clinically
important parameters, using cases performed within a single hospital
by the same team of interventional radiologists.
In this study, we demonstrated that CBCT guidance with real-time
imaging was a highly accurate diagnostic method for biopsy of lung
nodules, with reduced procedure time compared to CCT. Diagnostic
accuracy was comparable between CBCT and CCT groups, with only
one false-negative result under CBCT guidance. CCT-guided
percutaneous biopsies have been extensively shown in various studies
to be reliable in the hands of experienced operators, with accuracy
ranging from 74% to 83.9% in earlier investigations [15,16] to 90%
in a more recent study [3]. A higher mean diagnostic accuracy for
CBCT-guided percutaneous lung biopsy has been reported by
previous authors, ranging from 92% to 98% [14,17,18], and results
from our patients compared favorably to these studies. A factor in the
low diagnostic accuracy of CCT guidance may be the difficulty of
approaching small lesions in the lower lobes, which are more affected
by respiratory movements [22,24]. This problem is compounded in
patients for whom respiratory control is difficult or impossible. Withthe addition of real-time visualization during needle insertion,
operators of CBCT-guided systems may be able to biopsy lesions in
the lower lobes and in elderly patients with greater speed and reduced
radiation exposure, as was demonstrated in our study (Table 3). This
was consistent with earlier investigations that found advantages in terms
of reduced procedure time and dose when using conventional
fluoroscopy guidance for pulmonary biopsies over CT, since cone-beam
CT is, in essence, a combination of fluoroscopy and CT [23,27].
Although Choo et al. [19] reported a reduction in total procedure
time (defined as time from local anesthesia to completion of
post-biopsy CBCT) compared to published data on CT-guided
biopsy, they did not compare patients performed at a single
institution. In the present study, total procedure time was defined
as the interval from start of first planning CT scan to the last
post-procedure scan to take into account any potential time difference
in planning needle insertion and path to target between CBCT and
CCT systems. By using the internal clocks of the imaging systems
themselves to record time, more accurate and reproducible interval
measurements can also be obtained. A consistent and statistically
significant difference was found in the mean procedure time, and a
higher number of successful needle passes can be maintained during
this shorter time period using the real-time visualization provided by
CBCT. The potential for greater flexibility in selection of skin entry
site and reduced dependence on patient’s physical condition are of
great value for both operators and patients, as is the ability to avoid
overlying ribs and other structures [24]. Another aspect of performing
biopsies with cone-beam CT that may be advantageous is the reduced
room time used for biopsies in CCT systems, which may decrease
waiting time and simplify scheduling for patients requiring diagnostic
CT scans. Since CBCT is normally used for neuroradiology and
angiographic examinations and interventions, scheduling biopsy
patients during downtimes between examinations may also prove
economical in terms of asset utilization.
Comparison of radiation DAP values between CBCT systems can
usually be made directly since the amount of radiation output is
accurately recorded by the imaging system itself. [20] The mean DAP
in our CBCT group was 18757 ± 11300 mGy cm2 (not shown in
results), which was modest compared to the 10,717.78 ± 11,043 to
50,794.7 ± 28,251.4 mGy cm2 range of DAP values reported in
several recent studies [14,17,19,23,24]. Although DAP is convenient
for comparison between CBCT systems, many investigators in recent
studies eschew this parametric in favor of effective dose, which allows
better correlation with CT-guided procedures. Varying levels of
effective radiation dose for CBCT guidance have been reported by
different investigators, with some reporting a lower dose (CBCT:
5.72 mSv and CCT: 11.05 mSv by Choo et al. [19], CBCT: 4.6 mSv
and CCT: 10 mSv by Hwang et al. [20]), while others saw higher
doses (8.6 mSv by Choi et al. [14]). The CBCT conversion factor
used to obtain effective dose from measured DAP in this study was
0.183 mSv/Gy cm2, as cited from Braak et al. [8] who used the same
CBCT imaging system in their 2011 study. The corresponding factor
used for CCT was 0.02 mSv/mGy cm [25]. Effective radiation dose
in our study was 3.4 mSv for the CBCT group and 3.9 mSv for the
CCT group, which compare favorably with these studies. The
markedly lower CT dose in the present study may be explained by the
low-dose mode used during biopsy planning and post-procedure.
Despite patients being on average 7 years older than in the CCT
group, CBCT-guided biopsies in our study were performed more
quickly. Especially striking was the time difference for patients older
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CBCT cases. Given that higher age did not correspond to increased
complication rates, there may be significant benefits to considering
CBCT for pulmonary biopsies in elderly patients. Additionally, it
may be noted that mean nodule size for the CBCT group was smaller
(30 mm to 35 mm) and lesion depth was greater (43 mm to 37 mm),
both of which are factors that have been previously shown to cause
diagnostic failures for CCT-guided biopsies [15,28]. Indeed, while a
diagnostic accuracy of 77.2% was reported for nodules smaller than
20 mm [28], our own results indicated a 100% accuracy for lesions of
this size and smaller biopsied under CBCT. Lee et al. also noted in
their study that the real-time imaging guidance capability and high
flexibility in entry site selection of cone-beam CT systems contributes
to high diagnostic accuracy in small lesions [24]. Of course, very small
lesions can still pose problems for accuracy and post-biopsy
complications even under CBCT guidance, and in the same study,
it was found that a lesion size of 1 cm or less is a significant
independent risk factor for diagnostic failure. Although an earlier
investigation by Choi et al. did not show any factors that significantly
decreased diagnostic accuracy with CBCT, ground-glass nodules were
found to be associated with increased risk of post-biopsy hemoptysis
[14]. Despite these potential caveats, the fact that small and difficult
to access nodules were biopsied in less time and with decreased dose
(in the case of lower lobe lesions, as shown in Table 3) suggested a
potential role for recruiting patients at high risk of biopsy failure with
CCT to cone-beam CT systems for biopsy, provided that radiologists
experienced with CBCT-guided procedures are available.
Pneumothorax and hemoptysis are the most common complica-
tions of percutaneous needle biopsy for lung lesions [21,22]. Patients
at increased risk of pneumothorax include those with preexisting lung
disease, increased number of needle passes, greater lesion depth,
patient age, and needle size [5,15,21,22]. Pneumothorax rate in our
series of CBCT-guided needle biopsy was equal to the CCT biopsy
group at 20%, which fell within previously reported ranges for
CT-guided lung biopsy, 13% to 45% [4,5,15,16,22]. It was also
comparable to several recent CBCT studies that reported a range of
15.4% to 31.8% [7,9,14,17–19]. Patients who suffered from
post-biopsy pneumothorax in the cone-beam group had a mean age
of 62 years, target lesion size of 2.8 cm, and pleura-to-lesion depth of
4.6 cm (for CCT: 62 years old, lesion size of 3.6 cm and lesion depth
of 4.0 cm). It must be noted that despite having almost all of the risks
for increased pneumothorax, CBCT-guided biopsy patients in the
present study did not suffer from increased post-procedure
complications compared to their CCT counterparts. This fact is
certainly aided by the ability of cone-beam CT systems to visualize
relative positions of biopsy needle and target lesion in real time.
Hemoptysis is the next most significant post-biopsy complication
after pneumothorax, with incidence rates that tend to vary
significantly in the literature from 0% to 14% depending on patient
condition and biopsy protocol. [4,5,9,17–19]. While immediate
post-biopsy hemoptysis occurred slightly more frequently in our
CBCT-FNB group (CBCT: 11%, CCT: 7%, P = .47), it may be
explained by the generally more difficult biopsy conditions in the
CBCT group as noted above, especially greater lesion depth [24]. It
should also be noted that more passes were made with the cutting
needle in the CBCT group (four passes on average, compared to 2.6
times in the CCT group).
We report a major complication rate of 3% in our CBCT group, a
single patient who required endotracheal intubation because ofprogressive breathing difficulty and hypoxia. After reviewing his
medical history, we believe that the chronic obstructive pulmonary
disease, which he had been treated for more than 20 years, and his
subsequently diminished baseline pulmonary function (FEV1 was
34% of predicted) were major contributing factors in his post-
procedural respiratory failure. According to Manhire et al. [26],
patients with FEV1 b 35% of predicted should not undergo
percutaneous needle biopsy without careful risk assessment. Adhering
to this recommendation may have prevented the serious post-biopsy
complications experienced by the patient in our present study.
There were some limitations to this study. First, no randomized
comparison was made between CBCT and CCT guidance, although
this was mitigated to a certain extent by similar demographic and
physical characteristics of the patients enrolled in this study. A
prospective randomized study between these two techniques would
still be of great value in better judging their respective benefits and
drawbacks. Second, although using established conversion parameters
allow a reasonably accurate comparison between CBCT and CCT
imaging platforms, a more robust and universally accepted framework
on calculating effective radiation dose would certainly be of
exceptional value in future investigations. Lastly, a larger number of
patients in the CBCT group would add to the generalizability of this
study. However, given the consistently high accuracy and safety of
CBCT-guided systems along with ease of operation and real-time
feedback, we believe they can be of great benefit in clinical practice.
In conclusion, CBCT guidance with real-time guiding software
appears to significantly reduce procedure times for patients receiving
PTLBs, while maintaining high accuracy and safety in technically
challenging situations compared to CCT systems. Our study
demonstrated that under CBCT guidance, biopsy duration may be
safely reduced in elderly patients even with small nodules at greater
depth than CCT. There was also a notable reduction in radiation dose
in locations such as the lower lobes where respiration control may be
difficult to achieve. For clinicians considering whether a difficult-
to-access pulmonary nodule is feasible for transthoracic biopsy,
CBCT provides a valuable alternative to CCT while at the same time
freeing up CT systems for diagnostic examinations.
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